TABLE 2

Distribution of responders based on patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV1) by subgroup

Patients#TDICCQCATFEV1
Age years
 <652077993 (47.8)610 (29.4)817 (39.3)874 (42.1)
 ≥6522471015 (45.2)563 (25.1)768 (34.2)806 (35.9)
Sex
 Female1416648 (45.8)416 (29.4)531 (37.5)505 (35.7)
 Male29081360 (46.8)757 (26.0)1054 (36.2)1175 (40.4)
Smoking status
 Current smoker22921106 (48.3)664 (29.0)878 (38.3)908 (39.6)
 Ex-smoker2028901 (44.4)507 (25.0)705 (34.8)772 (38.1)
 Never-smoker41 (25.0)2 (50.0)2 (50.0)0 (0.0)
Exacerbations in previous 12 months
 034411602 (46.6)941 (27.3)1277 (37.1)1359 (39.5)
 ≥1883406 (46.0)232 (26.3)308 (34.9)321 (36.4)
Baseline FEV1 % pred
 <60%1367617 (45.1)357 (26.1)476 (34.8)555 (40.6)
 ≥60%29481389 (47.1)816 (27.7)1108 (37.6)1124 (38.1)
Bronchodilator reversibility
 ≤12%32511521 (46.8)866 (26.6)1197 (36.8)1060 (32.6)
 >12%1067486 (45.5)307 (28.8)387 (36.3)619 (58.0)

Data are presented as n or n (%). TDI: Transition Dyspnoea Index; CCQ: Clinical COPD Questionnaire; CAT: COPD Assessment Test. #: total number of patients; some of the responders showed response to more than one PRO and/or FEV1.